dopamine quinone has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 1 studies
| Studies (dopamine quinone) | Trials (dopamine quinone) | Recent Studies (post-2010) (dopamine quinone) | Studies (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) | Trials (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) | Recent Studies (post-2010) (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) |
|---|---|---|---|---|---|
| 61 | 0 | 29 | 3,859 | 8 | 1,052 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishimaru, Y; Maeda, S; Sugino, Y; Yamamuro, A; Yoshioka, Y | 1 |
1 other study(ies) available for dopamine quinone and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
Dopamine inhibits the expression of proinflammatory cytokines of microglial cells through the formation of dopamine quinone in the mouse striatum.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Line; Corpus Striatum; Cytokines; Depression, Chemical; Dopamine; Gene Expression; Inflammation Mediators; Interleukin-1beta; Male; Mice, Inbred C57BL; Microglia; RNA, Messenger; Tumor Necrosis Factor-alpha | 2022 |